Drugs / GS-3583
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04747470 | Mar 2021 → Nov 2022 | cancer | Gilead Sciences | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-3583 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04747470 ↗ |
| Action | Activate | “GS-3583, a FLT3 Agonist Fc Fusion Protein” NCT04747470 ↗ |
| Modality | Protein / enzyme biologic | “GS-3583, a FLT3 Agonist Fc Fusion Protein” NCT04747470 ↗ |
| Route | Intravenous | “Administered as an intravenous (IV) infusion” NCT04747470 ↗ |
| Target | FLT3 | “GS-3583, a FLT3 Agonist Fc Fusion Protein” NCT04747470 ↗ |